Company
(Symbol)^#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)

Acumen
Pharmaceuticals
Inc.*

Merck & Co. Inc.

$5

Milestone payment

Acumen received the payment in relation to its 2003 license agreement to research and develop disease-modifying therapies for Alzheimer's disease and other memory- related disorders (1/22)

BioCryst
Pharmaceuticals
Inc. (BCRX)

Mundipharma International Holdings Ltd. (UK)

$5

Milestone payment

Triggered by the start of a pivotal trial of Fodosine to treat relapsed or refractory T- cell leukemia/lymphoma (1/16)

Can-Fite
BioPharma*
(Israel)

Seikagaku Corp. (Japan)

$0.5

Milestone payment

Triggered by the completion of enrollment of 250 patients in a Phase IIb trial of CF101 in rheumatoid arthritis (1/16)

InterMune
Inc. (ITMN)

F. Hoffmann- La Roche Ltd. (Switzerland)

$10

Milestone payment

Triggered by completion of large-scale synthesis and delivery to Roche of the active pharmaceutical ingredient for the hepatitis C virus drug candidate ITMN-191 (1/9)

Medarex
Inc. (MEDX

ImClone Systems Inc. (IMCL)

ND

Milestone payment

Triggered by the FDA's acceptance of an IND for ImClone's IMC-3G3, an anticancer antibody developed using Medarex's UltiMAb technology (1/3)

NicOx SA
(France; Pink
Sheets:NICXF)

Merck & Co. Inc.

€5 (US$6.5)

Milestone payment

Triggered to the initiation of toxicology studies on the first development candidate selected by the companies from their March 2006 collaboration, which focused on use of NicOx's nitric oxide-donating technology (1/18)

Scolr Pharma
Inc.
(AMEX:DDD)

Wyeth Consumer Healthcare (division of Wyeth)

ND

Milestone payment

Company received a second milestone payment from its 2005 license agreement in which Wyeth has worldwide rights to use Scolr's CDT drug delivery platform in an over-the- counter formulation of an undis- closed agent (1/30)

Scynexis
Inc.*

Merck & Co. Inc.

$1

Milestone payments

Triggered by preclinical progress in their collaboration to develop antifungal agents (1/9)

The Immune
Response Corp.
(OTC BB:IMRP)

NovaRx Corp.*

$0.9

Milestone
payment

Triggered by a financing milestone reached by NovaRx, which in 2004 gained rights from Immune Response to cancer cell line vaccines (1/4)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.